Trial Profile
Phase 3 Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Of 2 Doses Of Tofacitinib In Patients With Active Rheumatoid Arthritis On Background Methotrexate
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Apr 2022
Price :
$35
*
At a glance
- Drugs Tofacitinib (Primary)
- Indications Rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Acronyms ORAL-Scan
- Sponsors Pfizer
- 05 Apr 2022 Results of post-hoc pooled analysis (ORAL Scan; ORAL Standard; ORAL Sync) assessing impact of tofacitinib on fatigue, sleep, and HRQoL and explored associations between fatigue, related patient-reported outcomes (PROs), and disease activity in RA patients, published in the Arthritis Research and Therapy.
- 01 Mar 2022 Results evaluating the impact of tofacitinib using posthoc analysis of phase III and phase IIIb/IV trials published in The Journal of Rheumatology
- 05 Jun 2021 Results (n=2265) of post-hoc analysis from three trials (NCT00847613; NCT00853385, NCT00856544, NCT00661661 and NCT00413699) assessing the impact of sex on efficacy, safety and persistence in tofacitinib rheumatoid arthritis presented at the 22nd Annual Congress of the European League Against Rheumatism